Digital pills cut blood pressure faster
Patients with uncontrolled hypertension and type 2 diabetes using digital medicines had larger 4-week SBP drops than usual care.
Source
Effectiveness of Digital Medicines to Improve Clinical Outcomes in Patients with Uncontrolled Hypertension and Type 2 Diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial
Study at a glance
- Design
- RCT — Open-label cluster-randomized three-arm pilot: 4-week DMO, 12-week DMO, usual care
- N
- N=109 · Modified ITT (40 / 40 / 29) across 13 US primary-care sites
- Population
- Adults with uncontrolled hypertension and type 2 diabetes in US primary care
- Outcome
- SBP reduction, BP goal attainment, and LDL-C/HbA1c change to 12 weeks
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
Digital pills cut blood pressure faster
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
DMO produced ~9 mm Hg greater SBP reduction at 4 weeks.
In this study, participants with uncontrolled HTN and T2DM who used the DMO had significantly greater reductions in SBP within 4 weeks than the usual care group (9 mm Hg greater reduction), which was maintained at 12 weeks with a significantly greater proportion of patients achieving their BP goal.
Modified-ITT included 109 participants.
The final modified-ITT group included 109 participants (40 in 4-week DMO, 40 in 12-week DMO, and 29 in usual care) ().
What they did
A 12-week open-label cluster-randomized three-arm pilot at 13 US primary-care sites compared 4-week DMO, 12-week DMO, and usual care for uncontrolled HTN with T2DM.
What they found
DMO users had about 9 mm Hg greater SBP reduction by week 4, more patients at BP goal by week 12, and larger LDL-C declines; HbA1c also trended lower.
The limits
What it doesn't show
Long-term hard cardiovascular events, blinded placebo effects, or performance outside motivated primary-care clusters.
Key terms
- DMO
- Digital medicine offering—sensor-enabled medicines with adherence feedback.
- SBP
- Systolic blood pressure, the primary endpoint at week 4.
- Cluster randomization
- Sites—not individual patients—assigned to study arms.
- Modified ITT
- Analysis set after excluding a compromised usual-care site.
- LDL-C
- Low-density lipoprotein cholesterol, an exploratory lipid outcome.
- Uncontrolled HTN
- Blood pressure above target despite available treatments.
Flashcards
0 of 11 answers reviewed
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
Primary endpoint was:
Common questions
What was the primary endpoint?
Change in SBP from baseline to week 4.
How large was the analytic sample?
109 participants in the modified-ITT set.
How much greater was SBP reduction?
About 9 mm Hg greater with DMO by week 4.
What happened to LDL-C?
Greater reductions with DMO (−33.2 at week 4; −19.2 at week 12 vs usual care).
More on Treatment adherence